Raymond Perez
University of Kansas Medical Center · Dartmouth-Hitchcock Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Raymond Perez as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:40 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02001974 · Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)Dompé Farmaceutici S.p.A · completed · Metastatic Breast Cancer · principal investigator
- Ph1NCT00012194 · 7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid TumorsNational Cancer Institute (NCI) · terminated · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- PROTOCOL-SPECIFIC RESEARCH SUPPORTP30CA023108 · NCI · DARTMOUTH COLLEGE · fiscal years 2004 to 2014 · $124,348 awarded in 2014Same name and institution; not confirmed by an ID
- Inhibition of S14 by Conjugated Linoleic Acid in Advanced Solid Tumor PatientsR21CA131820 · NCI · DARTMOUTH COLLEGE · fiscal years 2009 to 2010 · $208,560 awarded in 2010Same name and institution; not confirmed by an ID
- SPRY2 predicts survival post-chemotherapy in advanced ovarian cancer.R21CA141083 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · fiscal years 2009 to 2010 · $86,461 awarded in 2010Same name and institution; not confirmed by an ID
- MODULATION OF CLINICAL SENSITIVITY TO CHEMOTHERAPYK24CA084081 · NCI · DARTMOUTH COLLEGE · fiscal years 2000 to 2004 · $129,924 awarded in 2004Same name and institution; not confirmed by an ID
- Atorvastatin, a prenylation inhibitor in acute leukemia.R21CA092949 · NCI · DARTMOUTH COLLEGE · fiscal years 2002 to 2003 · $213,202 awarded in 2003Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:40 UTC. The ranking covers the 200 most relevant of 144 PubMed records, and a shared surname and initials can bring in a namesake. All 144 on PubMed
- An ERP study of the temporal course of the Stroop color-word interference effect.Neuropsychologia · 2000476 citationsRCR 15.2
- Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?Dis Colon Rectum · 2013335 citationsRCR 11.6
- Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.Gastroenterology · 2006273 citationsRCR 7.5
- Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.Lancet Respir Med · 2020248 citationsRCR 12.2
- 245 citationsRCR 5.1
- 221 citationsRCR 10.4
- Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.Clin Cancer Res · 2017208 citationsRCR 6.5
- Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis.Lancet · 1991207 citationsRCR 7.4
- 199 citationsRCR 6.5
- Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.J Clin Endocrinol Metab · 2002195 citationsRCR 5.0